Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for rare liposarcoma

NCT ID NCT04794127

Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) could help shrink or control liposarcoma, a rare cancer of fat tissue. The study included 10 patients whose tumors had stopped growing but not shrunk with trabectedin alone. Researchers measured tumor response and side effects to see if the combination was safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
trabectedin and pioglitazone
What this could lead to
If it works, this combination could help shrink or control liposarcoma tumors that have stopped responding to trabectedin alone.
What could go wrong
This is a very small, early-phase study with only 10 participants. The results may not apply to all patients, and the combination may cause additional side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

Feb 2022

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of myxoid/round cell liposarcomas 2. Histological diagnosis confirmation by a reference centre 3. Age ≥ 18 years 4. ECOG PS ≤2 5. One or more previous systemic treatments employing anthracyclines +/- ifosfamide (unless one or both are clinically contraindicated) 6. Four or more previous cycles of T with a stable disease as defined by RECIST criteria 7. Recovery from toxic effects of prior therapies to NCI CTC Grade 1 or higher 8. Provision of signed informed consent Exclusion Criteria: 1. Pregnant or breast-feeding women 2. Partial response or progression disease as per RECIST criteria to the previous treatment with T 3. Inadequate haematological, renal and liver functions 4. History of other malignancies (except basal cell carcinoma or cervical carcinoma in situ, adequately treated), unless in remission from 5 years or more and judged of negligible potential of relapse 5. Known central nervous system (CNS) metastases 6. Active viral hepatitis or chronic liver disease 7. Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within one year before enrolment, uncontrolled arterial hypertension or arrhythmias 8. Active major infection 9. Other serious concomitant illnesses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liposarcoma, dedifferentiated are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma liposarcoma myxoid liposarcoma myxoid/round cell liposarcoma round cell liposarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liposarcoma, dedifferentiated Liposarcoma, myxoid Liposarcoma, round cell

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Nazionale Tumori

    Milan, MI, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.